Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling

Nuclear Medicine and Biology

Volumn 38, Issue 6, 2011, Pages 771-780

  Bowen, Stephen R ^a   van der Kogel, Albert J ^b   Nordsmark, Marianne ^c   Bentzen, Søren M ^a   Jeraj, Robert ^a,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

Cu ATSM; Electrochemical model; Eppendorf; FMISO; Hypoxia; PET; PO 2

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; DIACETYL DI(N4 METHYLTHIOSEMICARBAZONE) CU 61; OXYGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ACIDITY; ARTICLE; BIOTRANSFORMATION; CLINICAL ARTICLE; COMPUTER MODEL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG HALF LIFE; DRUG UPTAKE; ELECTROCHEMICAL ANALYSIS; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; IMAGE ANALYSIS; ISOTOPE TRACING; MICROELECTRODE; OXYGEN TENSION; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE STUDY; SQUAMOUS CELL CARCINOMA; STEADY STATE; TISSUE DISTRIBUTION; TISSUE OXYGENATION; TUMOR MICROENVIRONMENT;

BIOLOGICAL TRANSPORT; CELL HYPOXIA; COPPER RADIOISOTOPES; ELECTROCHEMISTRY; HEAD AND NECK NEOPLASMS; HUMANS; MISONIDAZOLE; MODELS, BIOLOGICAL; ORGANOMETALLIC COMPOUNDS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; REPRODUCIBILITY OF RESULTS; THIOSEMICARBAZONES; TIME FACTORS;

EID: 80051704096     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.02.002     Document Type: Article

References (35)

1. Thomlinson R., Gray L. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955, 9:539-549.
2. Vaupel P., Mayer A., Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004, 381:335-354.
3. Le Q.T., Courter D. Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev 2008, 27:351-362.
4. Nordsmark M., Bentzen S.M., Rudat V., Brizel D., Lartigau E., Stadler P., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77:18-24.
5. Arteel G.E., Thurman R.G., Raleigh J.A. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem 1998, 253:743-750.
6. Mees G., Dierckx R., Vangestel C., Van de Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009, 36:1674-1686.
7. Rasey J.S., Koh W.J., Grierson J.R., Grunbaum ZKrohn K.A. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989, 17:985-991.
8. Koh W.J., Rasey J.S., Evans M.L., Grierson J.R., Lewellen T.K., Graham M.M., et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992, 22:199-212.
9. O'Donoghue J.A., Zanzonico P., Pugachev A., Wen B., Smith-Jones P., Cai S., et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005, 61:1493-1502.
10. Troost E.G., Laverman P., Philippens M.E., Lok J., van der Kogel A.J., Oyen W.J., et al. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008, 35:1803-1811.
11. Mortensen L.S., Buus S., Nordsmark M., Bentzen L., Munk O.L., Keiding S., et al. Identifying hypoxia in human tumors: a correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode. Acta Oncol 2010, 49:934-940.
12. Sorger D., Patt M., Kumar P., Wiebe L.I., Barthel H., Seese A., et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003, 30:317-326.
13. Thorwarth D., Eschmann S.M., Holzner F., Paulsen F., Alber M. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006, 80:151-156.
14. Rajendran J.G., Schwartz D.L., O'Sullivan J., Peterson L.M., Ng P., Scharnhorst J., et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006, 12:5435-5441.
15. Obata A., Yoshimi E., Waki A., Lewis J.S., Oyama N., Welch M.J., et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 2001, 15:499-504.
16. Fujibayashi Y., Taniuchi H., Yonekura Y., Ohtani H., Konishi J., Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997, 38:1155-1160.
17. Holland J.P., Barnard P.J., Collison D., Dilworth J.R., Edge R., Green J.C., et al. Spectroelectrochemical and computational studies on the mechanism of hypoxia selectivity of copper radiopharmaceuticals. Chemistry 2008, 14:5890-5907.
18. Lewis J.S., McCarthy D.W., McCarthy T.J., Fujibayashi Y., Welch M.J. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999, 40:177-183.
19. Dehdashti F., Mintun M.A., Lewis J.S., Bradley J., Govindan R., Laforest R., et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003, 30:844-850.
20. Dehdashti F., Grigsby P.W., Lewis J.S., Laforest R., Siegel M.J., Welch B.A. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008, 49:201-205.
21. Osada M., Imaoka S., Sugimoto T., Hiroi TFunae Y. NADPH-cytochrome P-450 reductase in the plasma membrane modulates the activation of hypoxia-inducible factor 1. J Biol Chem 2002, 277:23367-23373.
22. Shi K., Souvatzoglou M., Astner S.T., Vaupel P., Nusslin F., Wilkens J.J., et al. Quantitative assessment of hypoxia kinetic models by a cross-study of dynamic 18F-FAZA and 15O-H2O in patients with head and neck tumors. J Nucl Med 2010, 51:1386-1394.
23. Wang W., Lee N.Y., Georgi J.C., Narayanan M., Guillem J., Schoder H., et al. Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer. J Nucl Med 2010, 51:37-45.
24. Avila-Rodriguez M.A., Nye J.A., Nickles R.J. Simultaneous production of high specific activity 64Cu and 61Co with 11.4 MeV protons on enriched 64Ni nuclei. Appl Radiat Isot 2007, 65:1115-1120.
25. Reischl G., Dorow D.S., Cullinane C., Katsifis A., Roselt P., Binns D., et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA - first small animal PET results. J Pharm Pharm Sci 2007, 10:203-211.
26. Thorwarth D., Eschmann S.M., Paulsen F., Alber M. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol 2005, 50:2209-2224.
27. Oxtoby D.W., Gillis H.P., Nachtrieb N.H. Principles of modern chemistry 2002, Thomson Learning, Inc., Samford, CN. 5th ed.
28. Piert M., Machulla H.J., Becker G., Aldinger P., Winter E., Bares R. Dependency of the [18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol 2000, 27:693-700.
29. Nilsson J., Lind B.K., Brahme A. Radiation response of hypoxic and generally heterogeneous tissues. Int J Radiat Biol 2002, 78:389-405.
30. Holland J.P., Green J.C., Dilworth J.R. Probing the mechanism of hypoxia selectivity of copper bis(thiosemicarbazonato) complexes: DFT calculation of redox potentials and absolute acidities in solution. Dalton Trans 2006, 783-794.
31. Lodish H., Berk A., Matsudaira P., Kaiser C.A., Krieger M., Scott M.P., et al. Molecular cell biology 2004, W.H. Freeman and Company, New York. 5th ed.
32. Munro A.W., Noble M.A., Robledo L., Daff S.N., Chapman S.K. Determination of the redox properties of human NADPH-cytochrome P450 reductase. Biochemistry 2001, 40:1956-1963.
33. Tuschen G., Sackmann U., Nehls U., Haiker H., Buse G., Weiss H. Assembly of NADH: ubiquinone reductase (complex I) in Neurospora mitochondria. Independent pathways of nuclear-encoded and mitochondrially encoded subunits. J Mol Biol 1990, 213:845-857.
34. International series of monographs on chemistry 1991, Vol. 26:21. Oxford University Press, New York. D.T. Sawyer (Ed.).
35. Gerweck L.E. Tumor pH: implications for treatment and novel drug design. Semin Radiat Oncol 1998, 8:176-182.